Australia markets closed

4D Molecular Therapeutics, Inc. (FDMT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
25.70+0.06 (+0.23%)
At close: 04:00PM EDT
25.70 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.31B
Enterprise value 1.04B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)48.53
Price/book (mrq)4.27
Enterprise value/revenue 184.95
Enterprise value/EBITDA -3.55

Trading information

Stock price history

Beta (5Y monthly) 2.93
52-week change 344.22%
S&P500 52-week change 326.27%
52-week high 336.25
52-week low 39.44
50-day moving average 328.13
200-day moving average 319.56

Share statistics

Avg vol (3-month) 3661.41k
Avg vol (10-day) 3391.4k
Shares outstanding 551.16M
Implied shares outstanding 652.64M
Float 833.4M
% held by insiders 13.50%
% held by institutions 187.93%
Shares short (30 Apr 2024) 49.62M
Short ratio (30 Apr 2024) 416.44
Short % of float (30 Apr 2024) 419.50%
Short % of shares outstanding (30 Apr 2024) 418.81%
Shares short (prior month 28 Mar 2024) 49.32M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-136,200.00%

Management effectiveness

Return on assets (ttm)-17.29%
Return on equity (ttm)-25.53%

Income statement

Revenue (ttm)20.45M
Revenue per share (ttm)0.47
Quarterly revenue growth (yoy)-90.60%
Gross profit (ttm)N/A
EBITDA -116.55M
Net income avi to common (ttm)-104.56M
Diluted EPS (ttm)-2.58
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)525.91M
Total cash per share (mrq)10.17
Total debt (mrq)14.17M
Total debt/equity (mrq)2.36%
Current ratio (mrq)32.65
Book value per share (mrq)11.74

Cash flow statement

Operating cash flow (ttm)-76.97M
Levered free cash flow (ttm)-49.05M